Clinical Management of Cardiovascular Risk Factors in Diabetes
Presents the rationale for why physicians should more aggressively treat hypertension and other CV risk factors in their diabetic patients. Specific therapeutic regimens for reducing CV events in diabetic patients are presented, including BP lowering, management of lipid abnormalities, antiplatelet therapy, and glucose control.
What people are saying - Write a review
We haven't found any reviews in the usual places.
abnormalities ACE inhibitor achieved agents ALLHAT amlodipine angiotensin antihypertensive aspirin associated baseline beneﬁcial beneﬁt blood glucose Blood Pressure BP control Cardiovascular Events Cardiovascular Risk clinical trials compared coronary creatinine CV events CV risk decrease diabetes and hypertension diabetes mellitus Diabetes Study diabetic nephropathy diabetic patients diabetic subjects diet diuretic dose drugs dyslipidemia effects end point Figure ﬁrst follow-up glucose levels glycemic control goal BP HbA1C hyperglycemia hypertensive patients increased insulin resistance intake Intervention irbesartan LDL cholesterol lifestyle lipid lipoprotein lower BP medications metabolic syndrome metformin mg/d mg/day mg/dL microalbuminuria microvascular nondiabetic nonfatal obesity outcome patients with diabetes patients with hypertension patients with type placebo prevention proteinuria RAAS ramipril receptor reduced regimen renal disease renin retinopathy risk factors rosiglitazone signiﬁcant signiﬁcantly Sowers JR speciﬁc statin stroke Systolic Hypertension Table therapy tion treated triglycerides type 2 diabetes UKPDS vascular